ストックスクリーナーアプリを入手
3.56
0.00%
0.00
プレマーケット:
3.56
Agenus Inc (AGEN) 最新ニュース
Agenus Secures Dismissal of Investors’ Cancer Drug Class Action - Bloomberg Law News
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Agenus Escapes Investor Fraud Suit Over Cancer Drug - Law360
Agenus (NASDAQ: AGEN) director Armen paid salary in stock grant - Stock Titan
Agenus Q4 2025 earnings preview - MSN
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen - MarketBeat
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
MiNK Therapeutics (NASDAQ: INKT) names new financial leadership team - Stock Titan
Research Analysts Issue Forecasts for Agenus Q1 Earnings - MarketBeat
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - BioSpace
Agenus Reports 2025 Financial Results, Advances BOT+BAL to Phase 3 with Expanding Global Access - Oncodaily
Price Action: Will Agenus Inc benefit from rate cuts2026 Setups & Verified Trade Idea Suggestions - baoquankhu1.vn
Agenus stock price target reaffirmed at $8 by B.Riley on revenue growth - Investing.com
Agenus reinforces commitment to global access as new innovation advances - Traders Union
Agenus reports $4.2M in early access revenue for cancer therapy - Investing.com Canada
Agenus Inc. 2025 Annual Report: Immuno-Oncology Strategy, Lead Programs, and Recent Developments - Minichart
Agenus reports $4.2M in early access revenue for cancer therapy By Investing.com - Investing.com South Africa
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Agenus: Fourth Quarter Financial Results Overview - Bitget
Agenus: Q4 Earnings Snapshot - Barchart.com
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus Inc. (AGEN) Releases Q4 2025 Earnings: Revenue Up but Wider Net Loss, Cash Plunges - Quiver Quantitative
Agenus 2025 10-K: $114.2M Revenue, $(0.00) EPS - TradingView
Agenus (NASDAQ: AGEN) leans on cancer lead BOT/BAL amid cash risk - Stock Titan
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Agenus Reports 2025 Progress: BOT+BAL Immunotherapy Advances to Phase 3 with Global Early Access Programs - Oncodaily
Market Fear: Why is Agenus Inc stock going down2026 Dividend Review & Trade Opportunity Analysis Reports - baoquankhu1.vn
(AGEN.O) | Stock Price & Latest News - Reuters
Form 8K Agenus Inc For: 16 March - Investing.com
Agenus (AGEN) secures Zydus funding as BOT+BAL enters global Phase 3 - Stock Titan
Agenus posts 42 percent 2 year OS and $4.2 million initial revenue on BOT plus BAL programs - Traders Union
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
Earnings Scheduled For March 16, 2026 - Benzinga
Agenus Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Volume Summary: Should I invest in Agenus Inc before earningsMarket Performance Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Agenus to Announce Q4 Earnings on March 16 - Intellectia AI
Agenus Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Immuno-oncology initiatives expand to address unmet cancer needs, Agenus asserts - Traders Union
Agenus receives $20M payment from Zydus collaboration By Investing.com - Investing.com Canada
Agenus receives $20M payment from Zydus collaboration - Investing.com Nigeria
Agenus (AGEN) Secures $20M Milestone Payment from Zydus Partners - GuruFocus
Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - marketscreener.com
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
Agenus (AGEN) director Garo Armen takes 4,994 shares as stock salary - Stock Titan
Agenus warns most metastatic colorectal cancer cases are MSS, calling for innovation to tackle resistance - Traders Union
1.82%
大文字化:
|
ボリューム (24 時間):